Catalent Cuts Annual Forecast More Than Expected, Delays Earnings Report Again
Catalent Inc. shares rose after the troubled contract drug manufacturer gave investors some reassurance about a slashed fiscal
2023-05-19 22:16
Drugmakers Eye $23 Billion Biotech Argenx Ahead of Key Data
European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma
2023-05-17 16:15